A preclinical asset, MGL-3745 is also a THR β-selective agonist that could be a follow-on compound to MGL-3196.
Resmetirom is an investigational therapy and has not been approved by the FDA (or any other regulatory authority). Resmetirom
is only available for use in a clinical trial setting (ClinicalTrials.gov NCT03900429 and NCT04197479)
Website Developed by Alan Leff Associates, Inc.